DOCSLIB.ORG

Prevalence and Quantification of Geographic Atrophy Associated With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prevalence and Quantification of Geographic Atrophy Associated With Downloaded from http://bjo.bmj.com/ on August 18, 2017 - Published by group.bmj.com Clinical science Prevalence and quantification of geographic atrophy associated with newly diagnosed and treatment- naïve exudative age-related macular degeneration Anne Sikorav,1 Oudy Semoun,1 Sandrine Zweifel,2 Camille Jung,3 Mayer Srour,1 Giuseppe Querques,1,4 Eric H Souied1 10–14 ► Additional material is ABSTRACT develop, causing further vision loss. Most published online only. To view Objective To identify and quantify geographic atrophy studies focus on either wet or dry form separately please visit the journal online (GA) associated with neovascular age-related macular and there is a paucity of reports on both forms of (http:// dx. doi. org/ 10. 1136/ bjophthalmol- 2015- 308065). degeneration (AMD) at initial presentation using a AMD concomitantly in the same eye. There are fundus autofluorescence (FAF) semi-automated software recent published data regarding the prevalence of – 1Department of Ophthalmology, and to correlate the results with demographic and GA complicating exudative AMD at diagnosis,14 16 University Paris Est, Centre clinical data. with diverse results. Hospitalier Intercommunal de Creteil, Creteil, France Design Retrospective, observational study. In both atrophic and exudative AMDs, RPE 2Department of Ophthalmology, Methods The study population consisted of treatment- damage may be an important factor for visual loss. University Hospital Zurich, naïve patients with newly diagnosed neovascular AMD. The status of RPE can be studied by blue light Zurich, Switzerland Best-corrected visual acuity, fundus photographs, infrared fundus autofluorescence (FAF) imaging, which is a 3 Clinical Research Center, reflectance, FAF and spectral-domain optical coherence non-invasive imaging method that allows for topo- University Paris Est fl Creteil, Centre Hospitalier tomography were performed, associated with uorescein graphic mapping of lipofuscin distribution in the 17 18 intercommunal de Creteil, and indocyanine green angiographies. Identification of RPE cell monolayer in vivo. Various patterns Creteil, France GA was independently performed by three readers. of FAF in different stages of AMD have been 4 – Department of Ophthalmology, Quantification of atrophy areas was done using reported.19 22 Due to the absence of lipofuscin, University Vita Salute, San Raffaele Scientific Institute, RegionFinder Software (RFA), a semi-automated software atrophic areas in eyes with GA have a reduced Milan, Italy embedded in Spectralis device (Heidelberg Engineering, signal. The increased autofluorescence intensity in Germany). the perilesional zone of atrophy helps to predict 23 24 Correspondence to Results We included 206 eyes of 173 consecutive future atrophy progression. Using Region Dr Oudy Semoun, Department patients (72% female, mean age: 79.7±9.1 years). Type Finder Analyser (RegionFinder Software (RFA), of Ophthalmology, Centre I choroidal neovascularisation (CNV) was observed in Heidelberg Engineering, Heidelberg, Germany), a Hospitalier Intercommunal de Creteil, 40, avenue de 44.2% of eyes, type II CNV was observed in 20.9% and novel semi-automated customised software based Verdun, Creteil 94010, France; mixed CNV lesion was observed in 11.7%. Polypoidal on FAF imaging and embedded in Spectralis oudysemoun@ hotmail. com choroidal vasculopathy was diagnosed in 7.7% and type (Spectralis HRA+OCT; Heidelberg Engineering, III CNV was diagnosed in 15.5%. Analysis of FAF frames Heidelberg, Germany) atrophic patches can be The present research has showed that GA was associated with nAMD in 46/206 quantified and the spread of the total size can be been presented in ARVO 2014 25 26 annual meeting as a poster: eyes (22.3%). Taking into account data both from determined over time. “Incidence and quantification of Region Finder and multimodal imaging, our results In this retrospective observational case series, our geographic atrophy associated suggest that GA was present in 24.3% of eyes newly purpose was to determine the prevalence and to with neovascular age related diagnosed with exudative AMD. Mean size of GA was quantify GA complicating exudative AMD at first macular degeneration at initial 2 – presentation” (Poster number: 1.23±1.76 mm (range 0.03 7.39). presentation, using a multimodal analysis including D0050, programme number: Conclusion GA is associated with nAMD in 1/4 of RFA. 4940). cases at initial presentation. Combined imaging, including RFA is an effective tool to identify and quantify METHODS Received 2 November 2015 GA at diagnosis. We reviewed the charts of consecutive treatment- Revised 13 July 2016 Accepted 14 July 2016 naïve patients with exudative AMD, who presented Published Online First at University Eye clinic of Creteil, France, between 8 August 2016 INTRODUCTION August 2012 and August 2013. French Society of Age-related macular degeneration (AMD) is the Ophthalmology Ethics Committee approval was leading cause of blindness in patients aged over obtained for the retrospective review of the data. – 65 years in industrialised countries.1 3 The first Both eyes could be included in case of bilateral visible alterations of AMD are drusen and retinal exudative AMD. pigment epithelial (RPE) irregularities. This early Exclusion criteria included age under 50 years, stage of age-related maculopathy (ARM) may pro- any previous treatment for exudative AMD (such as gress to either geographic atrophy (GA) or exuda- laser photocoagulation, photodynamic therapy, tive AMD. The prevalence of GA is 3.5% in intravitreal injections of steroids or anti-vascular subjects older than 75 years and accounts for endothelial growth factor (VEGF)), myopia >−6D approximately half the prevalence of exudative (spherical equivalent), active intraocular inflamma- 4–6 To cite: Sikorav A, AMD. Approximately 11% of patients with atro- tion or any other retinopathy (such as hereditary Semoun O, Zweifel S, phic AMD eventually progress to the exudative retinal dystrophy, diabetic retinopathy, retinal – et al. Br J Ophthalmol form at 4 years of evolution.7 9 In some eyes with venous occlusion or epiretinal membrane) and 2017;101:438–444. choroidal neovascularisation (CNV), GA may also CNV attributable to other causes than AMD. 438 Sikorav A, et al. Br J Ophthalmol 2017;101:438–444. doi:10.1136/bjophthalmol-2015-308065 Downloaded from http://bjo.bmj.com/ on August 18, 2017 - Published by group.bmj.com Clinical science Missing information about FAF or media opacities or fundus atrophy. Measures of atrophy using RFA were performed by haemorrhages that prevented adequate imaging of FAF were not three independent retina specialists (AS, SZ and OS). The first considered as exclusion criteria in our study if additional two readers (AS and SZ) measured the size of atrophy together. imaging data (fluorescein angiography (FA) and spectral-domain Reader 3 (OS) had no insight in atrophy quantification of the optical coherence tomography (SD-OCT)) for grading of GA two previous readers and the values for reader 3 were all inde- were available and applicable. pendently measured. Grading of atrophy was evaluated as All patients underwent at baseline a detailed medical and follow: presence of atrophy on one imaging modality (FAF or ocular history, a complete ophthalmologic examination, which OCT or FA) with the readers unanimity (1), presence of atrophy included measurement of best-corrected visual acuity (BCVA) diagnosed by multimodal imaging with the readers unanimity using standard ETDRS charts, expressed as logarithm of the (2), presence of atrophy diagnosed by multimodal with the minimum of angle of resolution (logMAR),27 slit-lamp biomicro- readers majority (3), absence of atrophy, diagnosed by multi- scopy, intraocular pressure assessment, fundus biomicroscopy. modal imaging, with the readers majority (4), and grading not Retinal imaging was performed with a confocal scanning laser applicable (5). ophthalmoscope system (Spectralis HRA+OCT, Heidelberg Engineering, Germany) and included the acquisition of infrared Statistics reflectance (IRR 820 nm), FAF (excitation 488 nm, emission Qualitative variables were described in percentages and quantita- 500–700 nm), FA, indocyanine green angiography (ICGA) and tive variables were described by their mean with SD. SD-OCT. Images were recorded with a minimum of resolution Comparisons of qualitative variables were performed using the of 768×768 pixels. The field of view was set 30°×30° and χ2 or Fisher’s exact tests. Comparisons of medians were per- centred on the macula, defined as a 6 mm diameter area around formed using the Kruskal-Wallis or Mann-Whitney tests. the fovea. Univariate and multivariate analyses with logistic regression A modified ETDRS grid, with circle diameters of 1200, 3600 were used to determine factors associated with atrophy at initial and 7200 mm (foveal, juxtafoveal and extrafoveal, respectively), presentation. In case of atrophy, predictive factors of visual was placed on the foveal centre using the Spectralis software. acuity and size of atrophy were determined using univariate and CNV lesion type (occult or type 1, classic or type 2, mixed, multivariate analyses with linear regression. Variables analysed retinal angiomatous proliferation (RAP) or type 3 and polypoi- were the following: age, sex, visual acuity, lens status, vitamin dal choroidal vasculopathy (PCV)) and their localisation using supplementation, CNV type, size and localisation of atrophy the ETDRS grid (subfoveal, juxtafoveal, extrafoveal) were first and
Load more

Recommended publications
  • The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
    The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration Monika Fleckenstein, MD,1 Paul Mitchell, MD, PhD,2 K. Bailey Freund, MD,3,4 SriniVas Sadda, MD,5,6 Frank G. Holz, MD,1 Christopher Brittain, MBBS,7 Erin C. Henry, PhD,8 Daniela Ferrara, MD, PhD8 Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to pro- gressive and irreversible loss of visual function. Geographic atrophy is defined by the presence of sharply demarcated atrophic lesions of the outer retina, resulting from loss of photoreceptors, retinal pigment epithelium (RPE), and underlying choriocapillaris. These lesions typically appear first in the perifoveal macula, initially sparing the foveal center, and over time often expand and coalesce to include the fovea. Although the kinetics of GA progression are highly variable among individual patients, a growing body of evidence suggests that specific characteristics may be important in predicting disease progression and outcomes. This review synthesizes current understanding of GA progression in AMD and the factors known or postulated to be relevant to GA lesion enlargement, including both affected and fellow eye characteristics. In addition, the roles of genetic, environ- mental, and demographic factors in GA lesion enlargement are discussed. Overall, GA progression rates reported in the literature for total study populations range from 0.53 to 2.6 mm2/year (median, w1.78 mm2/year), assessed primarily by color fundus photography or fundus autofluorescence (FAF) imaging. Several factors that could inform an individual’s disease prognosis have been replicated in multiple cohorts: baseline lesion size, lesion location, multifocality, FAF patterns, and fellow eye status.
    [Show full text]
  • Specialist Clinic Referral Guidelines OPHTHALMOLOGY
    Specialist Clinic Referral Guidelines OPHTHALMOLOGY COVID-19 Impact — Specialist Clinics As part of Alfred Health’s COVID-19 response plan, from October significant changes have been made to Specialist Clinic (Outpatient) services. All referrals received will be triaged; however, if your patient’s care is assessed as not requiring an appointment within the next three months, the referral may be declined. Where possible, care will be delivered via telehealth (phone or video consultation). Please fax your referral to The Alfred Specialist Clinics on 9076 6938. The Alfred Outpatient Referral Form is available to print and fax. Where appropriate and available, the referral may be directed to an alternative specialist clinic or service. You will be notified when your referral is received. Your referral may be declined if it does not contain essential information required for triage, or if the condition is not appropriate for referral to a public hospital, or is a condition not routinely seen at Alfred Health. The clinical information provided in your referral will determine the triage category. The triage category will affect the timeframe in which the patient is offered an appointment. Referral to Victorian public hospitals is not appropriate for: Review or treatment of neovascular (wet) age-related macular degeneration (AMD) where the patient has already commenced treatment at another facility Early intermediate or geographic atrophy (dry) age-related macular degeneration. If the patient is not willing to have surgical treatment Cataract that does not have a significant impact on the person’s activities of daily living Prior to the person’s vision being corrected with spectacles, contact lenses, or the use of visual aids.
    [Show full text]
  • INHERITED RETINAL DISEASE ¨ Hundreds of Causative Mutations Now Identified ¤ Most Affecting Photoreceptors Or RPE
    9/4/18 Hereditary Retinal Diseases Epidemiology ¨ HRDs affect about 1/2000 people worldwide INHERITED RETINAL DISEASE ¨ Hundreds of causative mutations now identified ¤ Most affecting photoreceptors or RPE ¨ Many associated with systemic syndromes Blair Lonsberry, MS, OD, MEd., FAAO ¨ Most cause significant visual disability Professor of Optometry Pacific University College of Optometry [email protected] ! Hereditary Retinal Disease! The Rod/Cone Dichotomy ! Signs and Symptoms Based on Photoreceptors Peripheral (Rod) Diseases Central (Cone) Diseases ! Involved: ¨ Retinitis Pigmentosa family ¨ Achromatopsia ! ¤ Leber’s Congenital Amaurosis ¨ Cone Dystrophy RODS CONES ¨ CSNB • Loss of Night Vision • Decreased Acuity ¨ Oguchi’s ¨ Stargardt’s juvenile • Peripheral Field Loss • Central scotoma macular ¨ Best’s dystrophies • ERG: Scotopic loss • ERG: Photopic loss • VA and color vision affected late • Color Vision Affected •Photosensitivity • Photosensitivity Case History/Entrance Skills Health Assessment 5 6 ¨ 31 YR HM ¨ SLE: ¨ CC: referred from PCP for a possible uveitis ¤ 1+ conjunctival injection in the right eye ¨ LEE: 3 years ago ¤ Anterior chamber: deep and quiet (no cells or flare ¨ PMHx: unremarkable noted in either eye) ¨ Meds: Omega-3 supplements ¨ Entrance VA: 20/30+ OD, OS ¨ IOP: 12 and 11 OD, OS ¨ Refraction: ¨ DFE: see photos ¤ +0.75 -2.50 x 003 6/7.5+ (20/25+) ¤ +0.25 -2.75 x 004 6/7.5+ (20/25+) ¨ All other entrance skills unremarkable except for difficulty doing confrontation visual fields 1 9/4/18 OS 7 OS OD 8 OD Retinitis
    [Show full text]
  • Visual Impairment Age-Related Macular
    VISUAL IMPAIRMENT AGE-RELATED MACULAR DEGENERATION Macular degeneration is a medical condition predominantly found in young children in which the center of the inner lining of the eye, known as the macula area of the retina, suffers thickening, atrophy, and in some cases, watering. This can result in loss of side vision, which entails inability to see coarse details, to read, or to recognize faces. According to the American Academy of Ophthalmology, it is the leading cause of central vision loss (blindness) in the United States today for those under the age of twenty years. Although some macular dystrophies that affect younger individuals are sometimes referred to as macular degeneration, the term generally refers to age-related macular degeneration (AMD or ARMD). Age-related macular degeneration begins with characteristic yellow deposits in the macula (central area of the retina which provides detailed central vision, called fovea) called drusen between the retinal pigment epithelium and the underlying choroid. Most people with these early changes (referred to as age-related maculopathy) have good vision. People with drusen can go on to develop advanced AMD. The risk is considerably higher when the drusen are large and numerous and associated with disturbance in the pigmented cell layer under the macula. Recent research suggests that large and soft drusen are related to elevated cholesterol deposits and may respond to cholesterol lowering agents or the Rheo Procedure. Advanced AMD, which is responsible for profound vision loss, has two forms: dry and wet. Central geographic atrophy, the dry form of advanced AMD, results from atrophy to the retinal pigment epithelial layer below the retina, which causes vision loss through loss of photoreceptors (rods and cones) in the central part of the eye.
    [Show full text]
  • Polypoidal Choroidal Vasculopathy-Associated Vitreous Haemorrhage Presenting As Hyphema Srikanta Kumar Padhy, Atul Kumar, Rebika Dhiman, Karen Sharma
    Images in… BMJ Case Rep: first published as 10.1136/bcr-2018-227547 on 13 December 2018. Downloaded from Polypoidal choroidal vasculopathy-associated vitreous haemorrhage presenting as hyphema Srikanta Kumar Padhy, Atul Kumar, Rebika Dhiman, Karen Sharma Dr Rajendra Prasad Centre for DESCRIPTION Ophthalmic Sciences, All India A 59-year-old Indian male patient presented to our Institute of Medical Sciences, clinic with sudden-onset, painless diminution of New Delhi, Delhi, India vision in the right eye for the last 1 week. Records from previous follow-up (2 months back) showed Correspondence to Dr Srikanta Kumar Padhy, that his vision was 20/200 right eye (OD) and 20/80 srikantkumar. padhy19@ gmail. left eye (OS). He had no known systemic medical com conditions. He was diagnosed as a case of right eye pseudophakia with polypoidal choroidal vascu- Accepted 13 November 2018 lopathy (figure 1A), as evidenced by his previous fundus fluorescein angiography (FFA) (figure 1B), indocyanine green angiography (ICGA) (figure 1C) and swept source optical coherence tomography (SSOCT) (figure 2A,C). He has been on regular follow-up for the same condition for the past 4 years. During the course, he had received four intravitreal antivascular endothelial growth factor (anti-VEGF, aflibercept 2 mg in 0.05 mL) injections, with the last injection being administered 4 months back. On ocular examination, his best-corrected visual acuity was hand movement close to face OD and 20/80 OS. Intraocular pressure was 16 mm Hg OD Figure 2 (A,C) Swept source optical coherence and 14 mm Hg OS. On slit lamp examination, pres- tomography (SSOCT) imaging of the right eye showing ence of hyphema (figure 3A) was noted in the right thumb-shaped pigment epithelial detachment (long eye obscuring the details of the rest of the ante- arrow) with double-layer sign (short arrow).
    [Show full text]
  • Cellular Functional Architecture of the Human Cone Photoreceptor Mosaic
    Cellular Functional Architecture of the Human Cone Photoreceptor Mosaic By William Scott Tuten A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Vision Science in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Austin Roorda, Chair Professor Susana Chung Professor Gerald Westheimer Fall 2014 Cellular Functional Architecture of the Human Cone Photoreceptor Mosaic © 2014 by William Scott Tuten Abstract Cellular Functional Architecture of the Human Cone Photoreceptor Mosaic by William Scott Tuten Doctor of Philosophy in Vision Science University of California, Berkeley Professor Austin Roorda, Chair Chromatic and high-acuity aspects of vision are mediated by cone photoreceptors, which sample the image relayed by the eye’s optics and transduce it into the neural signals that give rise to perception. Our understanding of how individual cones function has largely been gleaned from in vitro electrophysiological preparations, which allow the experimenter to stimulate single receptors while simultaneously recording their outputs. Building upon these findings requires investigating how signals arising from single sensory input neurons are handled downstream by the nervous system, up to and including the perceptual stage. With these goals in mind, the tools to approach these questions in vivo must be developed. The challenges associated with studying the perceptions arising from single sensory receptors are not trivial—doing so requires an ability to visualize and repeatedly stimulate the receptor of interest, which can be difficult when it is situated within a densely packed array of similar cells that is itself contained within a sensory organ. The eye, however, represents a unique case because the receptor layer can be visualized directly through the transparent cornea and lens.
    [Show full text]
  • The Development of a Clinical Trial Protocol and Functional Biomarkers for Age-Related Macular Degeneration
    The Development of a Clinical Trial Protocol and Functional Biomarkers for Age-Related Macular Degeneration Claire McKeague A thesis submitted to Cardiff University for the degree of Master of Philosophy SCHOOL OF OPTOMETRY AND VISION SCIENCES, CARDIFF UNIVERSITY 2014 SUPERVISED BY DR ALISON BINNS & DR TOM MARGRAIN DECLARATION This work has not previously been accepted in substance for any degree and is not concurrently submitted in candidature for any degree. STATEMENT 1 This thesis is being submitted in partial fulfillment of the requirements for the degree of …………………………(insert MCh, MD, MPhil, PhD etc, as appropriate) STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated. Other sources are acknowledged by explicit references. STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loan, and for the title and summary to be made available to outside organisations. Summary Age-related macular degeneration (AMD) is the leading cause of blindness amongst older adults in the developed world. With the predicted rise in the ageing population over the next decades, the prevalence of this debilitating disease will simply continue to increase. The only treatments currently available are for advanced neovascular AMD. The retina is already severely compromised by this stage in disease development. Therefore, there is a pressing need to evaluate potential novel interventions that aim to prevent the development of advanced disease in people with early AMD, to prevent sight loss from occurring. Furthermore, it is necessary to develop tests that are sensitive to subtle changes in visual function in order to evaluate the efficacy of these emerging treatments.
    [Show full text]
  • Common Eye Disorders in the Elderly – a Short Review
    CPD Article Common eye disorders in the elderly – a short review Visser L, FCOphth(SA), MMed(Ophth) Acting Head of Department of Ophthalmology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal Correspondence to: Dr Linda Visser, e-mail [email protected] Abstract As the eye ages, certain changes occur that may affect vision. Presbyopia is corrected by the use of reading glasses. Cataracts are common and vision can be restored following a reasonably simple operation. Visual loss due to glaucoma can be minimised by early detection and treatment, but once vision has been lost it cannot be recovered. Much research is being done on the treatment of age-related macular degeneration, but this currently remains the main cause of irreversible loss of vision in the elderly. Results of macular hole surgery are improving due to improved surgical techniques and better diagnostic equipment (Optical Coherence Tomography). Underlying vascular disease (systemic hypertension, diabetes, atherosclerosis, vasculitis) is usually present in patients with retinal artery occlusion, retinal vein occlusion or anterior ischaemic optic neuropathy. SA Fam Pract 2006;48(7): 34-38 Introduction of treatment has been measured in is the most common and one of the Loss of vision in the elderly can have terms of less loss of vision rather than earlier age-related disorders of the a multitude of causes. Often the a gain in vision. Recent advances in eyes. Symptoms of presbyopia usu- remedy is simple, for example pre- the treatment of AMD with intraocu- ally begin between the ages of 40 scribing spectacles (as in the case lar injections are however showing and 45 years, although they may be- of presbyopia) or a reasonably small promise with many patients regain- gin earlier in hyperopes (farsighted operation (as in the case of cata- ing some of the vision initially lost.
    [Show full text]
  • Related Macular Degeneration Perhaps You Have Just Learned That You Or a Loved One Has Age-Related Macular Degeneration, Also Known As AMD
    What you should know about age- related macular degeneration Perhaps you have just learned that you or a loved one has age-related macular degeneration, also known as AMD. If you are like many people, you probably do not know a lot about the condition or understand what is going on inside your eyes. What is AMD? AMD is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small spot near the center of the retina and the part of the eye needed for sharp, central vision, which lets us see objects that are straight ahead. In some people, AMD advances so slowly that vision loss does not occur for a long time. In others, the disease progresses faster and may lead to a loss of vision in one or both eyes. As AMD progresses, a blurred area near the center of vision is a common symptom. Over time, the blurred area may grow larger or you may develop blank spots in your central vision. Objects also may not appear to be as bright as they used to be. AMD can also interfere with simple everyday activities, such as the ability to see faces, drive, read, write, or do close work, such as cooking or fixing things around the house. The Macula The macula is made up of millions of light-sensing cells that provide sharp, central vision. It is the most sensitive part of the retina, which is located at the back of the eye.
    [Show full text]
  • Reducing Treatment Burden in Neovascular AMD
    Visit https://tinyurl.com/newgroundAMD for CME Monograph online testing and instant CME certificate. Reducing Treatment Burden in Neovascular AMD Original Release: November 1, 2020 Expiration: November 30, 2021 FACULTY Arshad M. Baruch D. Christina Y. Khanani, MD, MA Kuppermann, MD, PhD Weng, MD, MBA (CHAIR) This continuing medical education activity is provided by New York Eye and Ear Infirmary of Mount Sinai. This educational activity was developed and implemented in collaboration with MedEdicus LLC. This continuing medical education activity is supported through an unrestricted educational grant from Allergan. Distributed with LEARNING METHOD AND MEDIUM AMA CREDIT DESIGNATION STATEMENT IVERIC bio; jCyte; Novartis Pharmaceuticals This educational activity consists of a The New York Eye and Ear Infirmary of Corporation; and Regeneron Pharmaceuticals, supplement and ten (10) study questions. Mount Sinai designates this enduring material Inc. Honoraria from promotional, advertising The participant should, in order, read the for a maximum of 1.5 AMA PRA Category 1 or non-CME services received directly from learning objectives contained at the beginning Credits™. Physicians should claim only the commercial interests or their Agents (eg, of this supplement, read the supplement, credit commensurate with the extent of their Speakers Bureaus): Allergan. answer all questions in the post test, and participation in the activity. Christina Y. Weng, MD, MBA, had a financial complete the Activity Evaluation/Credit agreement or affiliation during the past year Request form. To receive credit for this activity, GRANTOR STATEMENT This continuing medical education activity is with the following commercial interests in the please follow the instructions provided on form of Consultant/Advisory Board: Alcon; the post test and Activity Evaluation/Credit supported through an unrestricted educational grant from Allergan.
    [Show full text]
  • Reading Performance in Blue Cone Monochromacy: Defining an Outcome Measure for a Clinical Trial
    Article Reading Performance in Blue Cone Monochromacy: Defining an Outcome Measure for a Clinical Trial Evelyn P. Semenov1, Rebecca Sheplock1, Alejandro J. Roman1, David B. McGuigan1, Malgorzata Swider1, Artur V. Cideciyan1, and Samuel G. Jacobson1 1 Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, USA Correspondence: Samuel G. Purpose: Blue cone monochromacy (BCM), a congenital X-linked retinal disease caused Jacobson, Scheie Eye Institute, by mutations in the OPN1LW/OPN1MW gene cluster, is under consideration for intrav- University of Pennsylvania, 51 N. itreal gene therapy. Difficulties with near vision tasks experienced by these patients 39th Street, Philadelphia, PA 19104, prompted this study of reading performance as a potential outcome measure for a future USA. e-mail: clinical trial. [email protected] Methods: Clinically and molecularly diagnosed patients with BCM (n = 17; ages Received: July 20, 2020 15–63 years) and subjects with normal vision (n = 22; ages 18–72 years) were examined Accepted: October 12, 2020 with the MNREAD acuity chart for both uniocular and binocular conditions. Parameters Published: December 8, 2020 derived from the measurements in patients were compared with normal data and also Keywords: clinical trial; cone; gene within the group of patients. Intersession, interocular and between-subject variabilities mutations; outcome measure; were determined. The frequent complaint of light sensitivity in BCM was examined by reading; visual acuity comparing results from black text on a white background (regular polarity) versus white on black (reverse polarity) conditions. Citation: Semenov EP, Sheplock R, Roman AJ, McGuigan DB, Swider M, Results: MNREAD curves of print size versus reading speed were right-shifted compared Cideciyan AV, Jacobson SG.
    [Show full text]
  • Functional and Cortical Adaptations to Central Vision Loss
    Visual Neuroscience ~2005!, 22, 187–201. Printed in the USA. Copyright © 2005 Cambridge University Press 0952-5238005 $16.00 DOI: 10.10170S0952523805222071 Functional and cortical adaptations to central vision loss SING-HANG CHEUNG and GORDON E. LEGGE Department of Psychology, University of Minnesota, Minneapolis (Received August 2, 2004; Accepted January 3, 2005! Abstract Age-related macular degeneration ~AMD!, affecting the retina, afflicts one out of ten people aged 80 years or older in the United States. AMD often results in vision loss to the central 15–20 deg of the visual field ~i.e. central scotoma!, and frequently afflicts both eyes. In most cases, when the central scotoma includes the fovea, patients will adopt an eccentric preferred retinal locus ~PRL! for fixation. The onset of a central scotoma results in the absence of retinal inputs to corresponding regions of retinotopically mapped visual cortex. Animal studies have shown evidence for reorganization in adult mammals for such cortical areas following experimentally induced central scotomata. However, it is still unknown whether reorganization occurs in primary visual cortex ~V1! of AMD patients. Nor is it known whether the adoption of a PRL corresponds to changes to the retinotopic mapping of V1. Two recent advances hold out the promise for addressing these issues and for contributing to the rehabilitation of AMD patients: improved methods for assessing visual function across the fields of AMD patients using the scanning laser ophthalmoscope, and the advent of brain-imaging methods for studying retinotopic mapping in humans. For the most part, specialists in these two areas come from different disciplines and communities, with few opportunities to interact.
    [Show full text]